Zacks Research Has Bearish Outlook for Novavax Q1 Earnings

Novavax, Inc. (NASDAQ:NVAX) – Research analysts at Zacks Research cut their Q1 2025 earnings per share estimates for Novavax in a research report issued to clients and investors on Wednesday, February 26th. Zacks Research analyst S. Ganoria now anticipates that the biopharmaceutical company will post earnings per share of ($0.65) for the quarter, down from their previous forecast of ($0.63). The consensus estimate for Novavax’s current full-year earnings is ($1.46) per share. Zacks Research also issued estimates for Novavax’s Q2 2025 earnings at $0.38 EPS, Q3 2025 earnings at ($0.39) EPS, Q4 2025 earnings at ($0.16) EPS, FY2025 earnings at ($0.83) EPS, Q1 2026 earnings at ($0.24) EPS, Q2 2026 earnings at $0.15 EPS, Q3 2026 earnings at $0.00 EPS and FY2026 earnings at $0.31 EPS.

Novavax (NASDAQ:NVAX) last posted its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.51) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.24. The firm had revenue of $88.31 million during the quarter, compared to the consensus estimate of $85.48 million. During the same quarter in the previous year, the company earned ($1.44) earnings per share.

Other analysts have also recently issued research reports about the company. BTIG Research initiated coverage on Novavax in a research report on Friday, February 28th. They set a “buy” rating and a $19.00 target price for the company. TD Cowen upgraded shares of Novavax to a “hold” rating in a research report on Thursday, February 27th. Finally, HC Wainwright reissued a “buy” rating and issued a $19.00 target price on shares of Novavax in a report on Tuesday, December 10th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Novavax currently has an average rating of “Hold” and an average price target of $18.00.

Novavax Stock Performance

Shares of Novavax stock opened at $7.68 on Monday. The company has a fifty day moving average of $8.48 and a 200 day moving average of $9.88. The company has a market capitalization of $1.23 billion, a P/E ratio of -3.40, a P/E/G ratio of 2.85 and a beta of 2.14. Novavax has a fifty-two week low of $3.81 and a fifty-two week high of $23.86.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of NVAX. GF Fund Management CO. LTD. purchased a new stake in shares of Novavax during the 4th quarter valued at $27,000. Spire Wealth Management purchased a new position in shares of Novavax in the 4th quarter valued at approximately $29,000. New Age Alpha Advisors LLC purchased a new stake in Novavax during the 4th quarter worth approximately $35,000. KBC Group NV increased its stake in Novavax by 97.0% during the 4th quarter. KBC Group NV now owns 7,954 shares of the biopharmaceutical company’s stock valued at $64,000 after purchasing an additional 3,917 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Novavax by 38.1% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,790 shares of the biopharmaceutical company’s stock worth $77,000 after buying an additional 1,598 shares during the last quarter. Institutional investors own 53.04% of the company’s stock.

Insider Activity at Novavax

In other Novavax news, Director James F. Young sold 5,400 shares of the stock in a transaction on Tuesday, December 31st. The stock was sold at an average price of $8.00, for a total transaction of $43,200.00. Following the sale, the director now owns 51,760 shares of the company’s stock, valued at approximately $414,080. This trade represents a 9.45 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Rachel K. King sold 4,150 shares of the company’s stock in a transaction on Friday, December 13th. The stock was sold at an average price of $9.02, for a total value of $37,433.00. Following the sale, the director now owns 14,770 shares of the company’s stock, valued at $133,225.40. This trade represents a 21.93 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 14,150 shares of company stock worth $119,641 in the last 90 days. 1.00% of the stock is owned by corporate insiders.

About Novavax

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.